Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents
We used a nationwide population registry in South Korea to estimate the effect of a second booster dose of mRNA COVID-19 vaccine on the risk for laboratory-confirmed SARS-CoV-2 infection, critical infection, and death in immunocompromised persons and long-term care facility (LTCF) residents. During...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2022-11-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/28/11/22-0918_article |
| _version_ | 1811338184667168768 |
|---|---|
| author | Yoo-Yeon Kim Young June Choe Jia Kim Ryu Kyung Kim Eun Jung Jang Seon Kyeong Park Do-Sang Lim Seonju Yi Sangwon Lee Geun-Yong Kwon Jee Yeon Shin Sang-Yoon Choi Mi Jin Jeong Young-Joon Park |
| author_facet | Yoo-Yeon Kim Young June Choe Jia Kim Ryu Kyung Kim Eun Jung Jang Seon Kyeong Park Do-Sang Lim Seonju Yi Sangwon Lee Geun-Yong Kwon Jee Yeon Shin Sang-Yoon Choi Mi Jin Jeong Young-Joon Park |
| author_sort | Yoo-Yeon Kim |
| collection | DOAJ |
| description |
We used a nationwide population registry in South Korea to estimate the effect of a second booster dose of mRNA COVID-19 vaccine on the risk for laboratory-confirmed SARS-CoV-2 infection, critical infection, and death in immunocompromised persons and long-term care facility (LTCF) residents. During February 16–May 7, 2022, among 972,449 eligible persons, 736,439 (75.7%) received a first booster and 236,010 (24.3%) persons received a second booster. Compared with the first booster group, at 30–53 days, the second booster recipients had vaccine effectiveness (VE) against all infections of 22.28% (95% CI 19.35%–25.11%), VE against critical infection of 56.95% (95% CI 29.99%–73.53%), and VE against death of 62.96% (95% CI 34.18%–79.15%). Our findings provide real-world evidence that a second booster dose of mRNA vaccine substantially increases protection against critical infection and death in these high-risk population groups.
|
| first_indexed | 2024-04-13T18:06:16Z |
| format | Article |
| id | doaj.art-3141521510474c7bbb2a48c6c288213f |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-04-13T18:06:16Z |
| publishDate | 2022-11-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-3141521510474c7bbb2a48c6c288213f2022-12-22T02:36:03ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592022-11-0128112165217010.3201/eid2811.220918Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility ResidentsYoo-Yeon KimYoung June ChoeJia KimRyu Kyung KimEun Jung JangSeon Kyeong ParkDo-Sang LimSeonju YiSangwon LeeGeun-Yong KwonJee Yeon ShinSang-Yoon ChoiMi Jin JeongYoung-Joon Park We used a nationwide population registry in South Korea to estimate the effect of a second booster dose of mRNA COVID-19 vaccine on the risk for laboratory-confirmed SARS-CoV-2 infection, critical infection, and death in immunocompromised persons and long-term care facility (LTCF) residents. During February 16–May 7, 2022, among 972,449 eligible persons, 736,439 (75.7%) received a first booster and 236,010 (24.3%) persons received a second booster. Compared with the first booster group, at 30–53 days, the second booster recipients had vaccine effectiveness (VE) against all infections of 22.28% (95% CI 19.35%–25.11%), VE against critical infection of 56.95% (95% CI 29.99%–73.53%), and VE against death of 62.96% (95% CI 34.18%–79.15%). Our findings provide real-world evidence that a second booster dose of mRNA vaccine substantially increases protection against critical infection and death in these high-risk population groups. https://wwwnc.cdc.gov/eid/article/28/11/22-0918_articleCOVID-19coronavirus diseaseSARS-CoV-2severe acute respiratory syndrome coronavirus 2virusesrespiratory infections |
| spellingShingle | Yoo-Yeon Kim Young June Choe Jia Kim Ryu Kyung Kim Eun Jung Jang Seon Kyeong Park Do-Sang Lim Seonju Yi Sangwon Lee Geun-Yong Kwon Jee Yeon Shin Sang-Yoon Choi Mi Jin Jeong Young-Joon Park Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents Emerging Infectious Diseases COVID-19 coronavirus disease SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 viruses respiratory infections |
| title | Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents |
| title_full | Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents |
| title_fullStr | Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents |
| title_full_unstemmed | Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents |
| title_short | Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents |
| title_sort | effectiveness of second mrna covid 19 booster vaccine in immunocompromised persons and long term care facility residents |
| topic | COVID-19 coronavirus disease SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 viruses respiratory infections |
| url | https://wwwnc.cdc.gov/eid/article/28/11/22-0918_article |
| work_keys_str_mv | AT yooyeonkim effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT youngjunechoe effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT jiakim effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT ryukyungkim effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT eunjungjang effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT seonkyeongpark effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT dosanglim effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT seonjuyi effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT sangwonlee effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT geunyongkwon effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT jeeyeonshin effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT sangyoonchoi effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT mijinjeong effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents AT youngjoonpark effectivenessofsecondmrnacovid19boostervaccineinimmunocompromisedpersonsandlongtermcarefacilityresidents |